Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GILEAD SCIENCES, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 74.10 USD | -1.12% | -0.98% | -13.69% | |
| Sep. 28 | GSK lifts growth ambitions for HIV business on long-acting drug | RE |
| Sep. 19 | Gilead Sciences Gets EU Committee's Positive Opinion on Expanding Veklury's Indication | MT |
Business Summary
- sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).
Number of employees : 17,000
Sales per Business
| USD in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 27,305 | 100.0 % | 27,281 | 100.0 % | -0.09% |
Sales per region
| USD in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
United States
69.2
%
| 19,267 | 70.6 % | 18,884 | 69.2 % | -1.99% |
Europe
16.4
%
| 4,874 | 17.9 % | 4,469 | 16.4 % | -8.31% |
Other International
14.4
%
| 3,164 | 11.6 % | 3,928 | 14.4 % | +24.15% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 2019 |
Mark Chao
PRN | Corporate Officer/Principal | - | - |
Andrew Dickinson
DFI | Director of Finance/CFO | 53 | 2019 |
Merdad Parsey
CTO | Chief Tech/Sci/R&D Officer | 60 | 2019 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 2021 |
Jacquie Ross
IRC | Investor Relations Contact | - | 2020 |
Adam Levy
PRN | Corporate Officer/Principal | - | - |
Cindy Perettie
PRN | Corporate Officer/Principal | - | May. 29 |
Joydeep Ganguly
PRN | Corporate Officer/Principal | - | - |
Dustin Haines
PRN | Corporate Officer/Principal | - | 2022 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Javier Rodriguez
BRD | Director/Board Member | 52 | 2020 |
Daniel O'Day
CHM | Chairman | 58 | 2019 |
Kevin Lofton
BRD | Director/Board Member | 68 | 2009 |
Anthony Welters
BRD | Director/Board Member | 68 | 2020 |
| Director/Board Member | 69 | 2018 | |
Kelly Kramer
BRD | Director/Board Member | 55 | 2016 |
| Director/Board Member | 70 | 2017 | |
Sandra Horning
BRD | Director/Board Member | 74 | 2020 |
| Director/Board Member | 69 | 2020 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 1,246,014,353 | 1,244,667,375 ( 99.89 %) | 0 | 99.89 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
GALAPAGOS NV 25.35% | 16,707,477 | 25.35% | 634,671,106 $ |
ARCUS BIOSCIENCES, INC. 19.90% | 14,823,029 | 19.90% | 303,872,095 $ |
ALLOVIR, INC. 14.61% | 16,635,286 | 14.61% | 52,068,445 $ |
ARCELLX, INC. 7.19% | 3,478,261 | 7.19% | 124,660,874 $ |
TANGO THERAPEUTICS, INC. 5.49% | 4,854,443 | 5.49% | 31,505,335 $ |
HOOKIPA PHARMA INC. 4.61% | 3,759,465 | 4.61% | 2,462,450 $ |
Company contact information
Group companies
| Name | Category and Sector | Since |
|---|---|---|
Gilead Sciences Ireland UC
|
-
| 2017 |
Gilead Therapeutics A1 Unlimited Co.
|
Health Technology - Pharmaceuticals: Major
| 2019 |
Sector
Sales per region
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
74.94USD
Average target price
91.36USD
Spread / Average Target
+21.92%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -13.69% | 93 376 M $ | |
| +83.43% | 1 229 M $ | |
| -.--% | 90 M $ | |
| +141.94% | 1 689 M $ | |
| +3.12% | 70 M $ | |
| +83.27% | 60 M $ | |
| +108.48% | 168 M $ | |
| -30.72% | 2 173 M $ | |
| +52.69% | 2 767 M $ | |
| -26.24% | 181 M $ |
